A
Alcista
Alcista · 25%LENZ
$37.95
Precio del escenario
$3.010
-0.392 (-13.01%)Al cierre
Loading chart…
- Máximo
- 3.440
- Apertura
- 3.440
- Precio medio ponderado por volumen
- 3.15
- Volumen
- 737.00K
- Capitalización
- —
- Mínimo
- 3.000
- Importe
- 2.32M
- EV/EBITDA, TTM
- -0.23
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Análisis de IA of LENZ Therapeutics Inc (LENZ)
ComprarLENZ Therapeutics Inc is a good buy right now at a current price of $3.05, especially considering its recent sales growth of 50% in Q3 2026, which indicates increasing market acceptance. The stock is currently oversold with an RSI of 36.13, suggesting potential for a rebound. However, the main risk is its significant year-to-date decline of 80.94%, which highlights volatility and uncertainty in the stock's recovery.
Métricas de valoración
El PER previsto actual de LENZ Therapeutics Inc (LENZ) es 0.00, frente a su media de 5 años de -10.36.
Escenarios de precio de Alphio AI para LENZ
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con LENZ en cartera
Cronología de eventos
Noticias
8.510-28NewsfilterLENZ Therapeutics Reports 50% Q3 Sales Growth and Strategic Reorganization
2.007-14NASDAQ.COMLenz Therapeutics Shares Enter Oversold Territory
- 8.507-06Newsfilter
LENZ Launches Telehealth Platform for VIZZ
- 7.506-24Newsfilter
LENZ and Arrotex Sign Exclusive License Agreement for VIZZ in Australia and New Zealand
8.506-12NASDAQ.COMBiotech Sector Sees Surge in FDA and Global Approvals
Preguntas frecuentes sobre LENZ, respondidas por Alphio AI
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
LENZ Therapeutics Inc is a good buy right now at a current price of $3.05, especially considering its recent sales growth of 50% in Q3 2026, which indicates increasing market acceptance. The stock is currently oversold with an RSI of 36.13, suggesting potential for a rebound. However, the main risk is its significant year-to-date decline of 80.94%, which highlights volatility and uncertainty in the stock's recovery.
Comunidad
Más ↗
$LENZ: LENZ Theutics approves reorganization, cutting 75% of staff and targeting over 50% lower 2027 operating expenses.
Mostrar másArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.